SeraCare Announces NASDAQ's Receipt of Request for HearingHearing Scheduled for February 2
January 09 2006 - 8:00AM
PR Newswire (US)
OCEANSIDE, Calif., Jan. 9 /PRNewswire-FirstCall/ -- SeraCare Life
Sciences, Inc. (NASDAQ:SRLSENASDAQ:SRLS), today announced that
NASDAQ has received the company's request to appeal the NASDAQ
Listing Qualification Staff's determination to delist the company's
securities from the NASDAQ National Market. NASDAQ has advised the
company that the delisting action has been stayed, pending a final
written decision by the NASDAQ Listing Qualifications Panel. The
request for a hearing date was filed on December 28, 2005. The
hearing is scheduled to be held on Tuesday, February 2, 2006 in
Washington, D.C. About SeraCare Life Sciences SeraCare Life
Sciences Inc. is a manufacturer and provider of biological products
and services to diagnostic, therapeutic, drug discovery, and
research organizations. The Company's offerings include
plasma-based therapeutic products, diagnostic products and
reagents, cell culture products, specialty plasmas, in vitro
stabilizers, and the SeraCare BioBank(TM), a proprietary database
of medical information and associated blood, plasma, DNA and RNA
samples. Headquartered in Oceanside, CA, SeraCare conducts business
throughout the world, and is traded on the NASDAQ national stock
market under the symbol SRLSE. For additional information about
SeraCare Life Sciences Inc., please visit the Company's Web site at
http://www.seracare.com/ . Contact: The Trout Group Tim Ryan,
212-477-9007x24 DATASOURCE: SeraCare Life Sciences, Inc. CONTACT:
Tim Ryan of The Trout Group, +1-212-477-9007, ext. 24, Web site:
http://www.seracare.com/
Copyright